ArticleThe oncologist2026
Novel genomic score predicts survival with immune checkpoint inhibition in neuroendocrine neoplasms.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibition (ICI) has activity in Grade 3 (G3) neuroendocrine neoplasms (NENs), but predictive biomarkers of long-term overall survival (OS) are currently lacking.
methodsWe derived a genomic scoring system using a retrospective cohort of 54 NEN patients treated with nivolumab and/or ipilimumab, alongside a chemotherapy-only control (n = 15) and pan-cancer validation cohort (n = 1661). An overall genomic score (GS-O) combining positive (GS-P) and negative response genes (GS-N) was calculated.
resultsIn the ICI cohort, patients with GS-O ≥ 2 had significantly better outcomes: median OS was not reached, compared to 3.9 months for low scores (HR = 0.007, P < .001). After multivariate adjustment, GS-P was independently associated with improved OS while GS-N showed a trend towards worsened OS. Importantly, GS-O ≥ 2 did not predict survival in the chemotherapy-alone cohort but was validated as independently predictive in the pan-cancer validation dataset (HR = 0.92, P < .001).
conclusionThis study establishes a novel genomic score to predict OS in NENs treated with ICI with important pan-cancer implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.